Compare ORMP & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORMP | IGI |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 98.7M |
| IPO Year | N/A | N/A |
| Metric | ORMP | IGI |
|---|---|---|
| Price | $2.88 | $16.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 260.9K | 33.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.79% |
| EPS Growth | ★ 838.25 | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.82 | $15.13 |
| 52 Week High | $3.09 | $17.79 |
| Indicator | ORMP | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 71.35 | 47.79 |
| Support Level | $2.38 | $16.37 |
| Resistance Level | $2.99 | $16.48 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 83.78 | 70.37 |
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.